---
run_id: halo-evidence-vs-diagnosis-validation-v11-generic-advice-prompted-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v11
benchmark_version: halo-evidence-vs-diagnosis-validation-v11-v1
model_condition: generic_advice_prompted
run_number: 3
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 305
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 18fa1d51f6167dbbf1f7ece676734d5cdb459384bca25e1508dd96cd4745e42d
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
condition_packet_sha256: 31fa87bc7ee0d210ab5e0070b5421b72beac068fc006b3bc3be78b3dd242d5e7
output_file: model-outputs/generic_advice_prompted-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v11-v1`, condition `generic_advice_prompted`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 305, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning and Tradeoffs
You are currently facing a "false positive" crisis. Your lagging indicators (bookings, renewals) look excellent, but your leading indicators (adjuster behavior, regional carrier feedback, health-liability abandonment) are flashing red.

The danger here is **confusing sales momentum with product-market fit.** The 16% rise in expansion bookings is heavily contaminated by the "bundle price" incentive and a roadmap pitch that promises future value. You aren't selling a tool that works; you are selling the *promise* of a tool that will eventually work.

Here is why the Claim File Review is the only viable path:

1.  **The "Manager Loop" Illusion:** Your usage data is misleading. A 39% increase driven by managers reviewing closed samples for training is "administrative usage," not "workflow utility." The fact that front-line adjusters abandon the tool after two days suggests SignalPath is a novelty, not a habit.
2.  **The Explainability Gap:** In the regulated health-liability segment, the product is failing a fundamental requirement: auditability. If an adjuster cannot explain a recommendation to a reviewer, the tool is a liability, not an asset.
3.  **The Failure of Other Options:**
    *   *Scaling broadly* based on current data is a gamble that could lead to massive churn in 12 months.
    *   The *Usage Quality Sprint* tracks "return rates," but a user can return to a tool and still override every suggestion. It measures engagement, not efficacy.
    *   The *Commercial Cleanroom* tells you if people will pay for it, but it doesn't tell you *why* they are stopping use. You already know the "why" from the regional carriers; you need to know if the product is actually solving the claim problem.

By performing a Claim File Review, you move from **proxies** (clicks and bookings) to **ground truth** (accepted vs. overridden actions). This is the only way to determine if SignalPath provides actual utility or if you are simply riding a wave of aggressive sales incentives.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and qualitative. It provides a "small set" of data that may not be statistically representative of your entire customer base. While the board is demanding a budget lock in 12 days, this review will not provide a definitive "yes/no" on the product's viability by that deadline. You are choosing deep insight over fast, quantitative (though potentially misleading) metrics.

### Observable Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the regional carriers who are removing SignalPath from their contracts are "outliers" (e.g., they have unique legacy tech stacks or unusual procurement rules) and that the "abandonment" in health-liability is purely a training issue rather than a fundamental lack of explainability in the AI's logic. If the friction is purely commercial or educational, rather than functional, then testing the pricing and pitch (the Cleanroom) becomes the priority.
